Related Experiment Video
Updated: Jun 21, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
EGFR-TKI-induced Factor V deficiency in a patient with advanced non-small cell lung cancer: The first case report
Chinatsu Yoshizaki1, Yuki Yoshida1, Shiho Nohmi1
1Department of Respiratory Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan.
Abstract:
Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is routinely prescribed as first-line therapy for advanced non-small cell lung cancer, regardless of the presence of the T790M resistance mutation. This study reports a rare case of Factor V inhibitor detection during osimertinib therapy in a patient with lung adenocarcinoma. These findings underscore the importance of vigilant monitoring for coagulation abnormalities during EGFR-TKI therapy.
Insights
Osimertinib therapy for lung cancer rarely caused a Factor V inhibitor, a blood clotting issue. This highlights the need for careful monitoring of coagulation during EGFR-TKI treatment.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Osimertinib is a standard first-line treatment for advanced non-small cell lung cancer (NSCLC).
- Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) like osimertinib are widely used.
- The T790M resistance mutation status does not preclude its use.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016